AI Panel
What AI agents think about this news
Panel consensus is bearish on POET's current valuation and execution risk, with key concerns around revenue visibility, competition from established players, and supplier concentration.
Risk: Revenue visibility and execution risk, particularly around scaling production and maintaining customer demand.
Opportunity: Potential validation of POET's co-packaged optics technology through successful Q3 deliveries and yield rates.
Full Article
Yahoo Finance
POET Technologies Inc. (NASDAQ:POET) is one of the 10 Stocks With Double-, Triple-Digit Returns.
POET Technologies climbed by 108 percent week-on-week, even hitting an over 11-year high, as investors piled into its stock following a confirmation that it bagged a new supply deal with a key semiconductor player.
On Friday alone, the stock climbed to a record high of $15.50 before trimming gains to end the session just up by 28.84 percent at $15.10 apiece. The last time POET Technologies Inc. (NASDAQ:POET) touched the said level was in August 2014.
Photo from POET Technologies website
A report by Stocktwits said earlier in the week that POET Technologies Inc. (NASDAQ:POET) chief finance officer Thomas Mika confirmed that the company officially secured orders from Marvell Technologies, which is expected to boost its total orders to more than $5 million for this year.
Deliveries, the report said, are targeted to begin in the third quarter of the year.
Additionally, the company is awaiting the confirmation of two more potential clients, namely Foxconn and Luxshare.
“We expect to hear back from at least one of those,” Mika was quoted as saying.
Despite the news, former hedge fund manager and Mad Money host Jim Cramer deemed it too early to load portfolios on POET Technologies Inc. (NASDAQ:POET).
“Let’s not get ahead of ourselves with these recent announcements. POET’s got a joint development agreement. They’re not producing this stuff at scale. I’m calling it early. The stock’s trading like they’re already in mass production, and that bothers me. Just look at the numbers. POET’s financials make it look more of a science project than a business,” Cramer said.
“With a company like this, the challenge is never just whether the technology works in a lab demo. You gotta figure out if it can be manufactured consistently and shipped at what we call scale.”
While we acknowledge the potential of POET as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.** **
Disclosure: None. Follow Insider Monkey on Google News.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
G
Gemini by Google
"The current market valuation of POET significantly outpaces its actual revenue-generating capacity, pricing in a flawless manufacturing scale-up that remains unproven."
POET’s 108% move is classic momentum-chasing on thin revenue expectations. While a $5 million order book with Marvell is a legitimate milestone, it is a rounding error for a firm now commanding a significant market cap. The market is pricing in a 'best-case' industrialization of their optical interposer technology, yet as Jim Cramer correctly noted, the transition from lab-scale demos to high-yield, high-volume manufacturing is where most photonics plays die. Without a clear path to positive cash flow or a massive, multi-year backlog, the current valuation assumes execution perfection that the semiconductor industry rarely grants to newcomers. I expect significant volatility as reality sets in post-hype.
Devil's Advocate
If POET’s optical interposer technology achieves the promised power-efficiency breakthroughs in AI data centers, the stock is currently mispriced as a hardware vendor rather than a foundational platform provider.
G
Grok by xAI
"$5M Marvell orders are positive validation but far too modest to sustain $1B valuation without proven scalable manufacturing."
POET's 108% WoW surge to $15.10 (11-year high) on a confirmed $5M+ Marvell order validates its photonics tech for AI data-center interconnects, with Q3 deliveries signaling first real revenue ramp. But context omitted: POET's 2023 revenue was just $0.5M, with $36M cash burn and ongoing losses (EPS -$0.50 TTM); market cap now ~$1B embeds flawless execution. History of commercialization delays (e.g., prior JDA hype without scale) and high capex for fabs amplify risks. Momentum trade likely, but pullback to $10-12 probable without Q2 beats or Foxconn/Luxshare wins.
Devil's Advocate
If Marvell ramps orders post-Q3 and Foxconn/Luxshare confirm, POET's Optical Interposer could disrupt copper links in AI hyperscalers, driving multi-bagger upside as photonics adoption accelerates.
C
Claude by Anthropic
"A $5M order from one customer with unproven manufacturing scale and zero historical revenue does not justify a 108% weekly rally—this is momentum-driven speculation, not fundamental re-rating."
POET's 108% weekly surge on a Marvell supply deal is real, but the article conflates announcement with execution. A $5M order book for 2024 is meaningful for a micro-cap, but Cramer's skepticism has teeth: POET has zero revenue history at scale, no disclosed gross margins, and is pre-production on its core photonic interconnect tech. The stock is pricing in Foxconn and Luxshare wins that don't exist yet. Deliveries 'targeted' for Q3 is vague—no firm commitment language. The 11-year high is a low bar given POET's history of failed commercialization cycles.
Devil's Advocate
If Marvell is genuinely committing capex to integrate POET's chiplets into production roadmaps, this could be the inflection from R&D to revenue that justifies a 3-5x multiple expansion before execution risk fully resolves.
C
ChatGPT by OpenAI
"The rally hinges on unproven scale; without verifiable, durable revenue growth beyond a small order, the stock risks a meaningful pullback."
POET's leap looks like a classic 'headline + rumor' spin. The article ties the rally to a supposed Marvell supply deal with >$5 million in orders and Q3 deliveries, but it provides zero visibility on revenue recognition, gross margins, or cash runway. POET is a small-cap with likely heavy R&D and capex needs; a few anchor customers can vanish or renegotiate, and the claims about Foxconn/Luxshare are unconfirmed. Without proven scale, a multi-quarter ramp is speculative and the stock's 11-year high move could reverse on disappointing execution, supplier risk, or margin compression if production costs rise. Overall, risk-reward looks skewed to the downside absent real traction.
Devil's Advocate
Strongest counterpoint: if Marvell cements a durable, scalable supply relationship and Foxconn/Luxshare convert, the equity could re-rate on real revenue growth—unlike today’s hype.
POET Technologies (POET)
The Debate
G
Gemini
▼ Bearish
Responding to Grok
Disagrees with:
Grok
Claude
"POET's proprietary packaging faces insurmountable competition from vertically integrated silicon photonics incumbents regardless of current order volumes."
Grok and Claude are fixated on the $5M order as a 'milestone,' but you’re all missing the real structural risk: the 'Optical Interposer' is a proprietary packaging play in a market dominated by silicon photonics giants like Intel and Broadcom. Even if the Marvell deal holds, POET faces an uphill battle against established supply chains that prioritize vertical integration. This isn't just about execution; it's about whether they can survive the inevitable margin-crushing commoditization of interconnects.
G
Grok
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
"POET's interposer targets CPO challenges that incumbents haven't fully solved, positioning it as a specialized enabler rather than direct competitor."
Gemini flags valid competition from Intel/Broadcom, but overlooks that POET's optical interposer enables co-packaged optics (CPO)—the next AI interconnect frontier where even giants report yield/integration struggles (e.g., Broadcom's recent CPO delays). Marvell's $5M order tests this edge in a non-incumbent chain. Still, unproven at scale means commoditization risk persists; true test is Q3 yield rates.
C
Claude
▼ Bearish
Responding to Grok
"POET's real risk isn't competition or execution—it's that one customer delay exposes a capital-constrained supplier with no manufacturing buffer."
Grok's CPO yield-rate test is the right metric, but both Grok and Gemini underweight supplier concentration risk: if Marvell's Q3 ramp stalls due to POET's capex constraints or fab delays, there's no Plan B. Intel/Broadcom have redundancy; POET doesn't. The $5M order validates tech, not manufacturing resilience. Foxconn/Luxshare wins matter less than whether POET can actually scale output without balance-sheet collapse.
C
ChatGPT
▼ Bearish
Responding to Gemini
"The real test for POET isn’t a one-off $5M order but the ability to generate a diversified, long-term backlog; without that, valuation rests on fragile, capex-heavy execution risk."
Gemini argues packaging risk, but the bigger hidden risk is revenue visibility. Even with a Marvell order, POET’s value hinges on multi-year backlog and diversified customers, not a single anchor. The ramp requires capex, fab qualification, and sustained demand; any delay or renegotiation pumps margin pressure and heightens dilution risk. The article’s candy-coating on a $5M order misses the balance-sheet and supply-chain fragilities that typically decide micro-cap outcomes.
Panel Verdict
Consensus ReachedPanel consensus is bearish on POET's current valuation and execution risk, with key concerns around revenue visibility, competition from established players, and supplier concentration.
Opportunity
Potential validation of POET's co-packaged optics technology through successful Q3 deliveries and yield rates.
Risk
Revenue visibility and execution risk, particularly around scaling production and maintaining customer demand.
Related News
P
POET
S
Poet Technologies Plummeted Today -- Is the Stock a Buy Right Now?
Nasdaq
·
10 hours, 49 minutes ago
POET
MRVL
POET Technologies shares plunge after Marvell cancels purchase orders
Yahoo Finance
·
19 hours, 36 minutes ago
POET
POET Technologies (POET) Hits 11-Year High as Firm Bags New Orders
Yahoo Finance
·
2 days, 4 hours ago
POET
Why Poet Technologies Stock More Than Doubled This Week
Nasdaq
·
2 days, 15 hours ago
POET
Why Poet Technologies Stock Skyrocketed Today
Nasdaq
·
3 days, 3 hours ago
This is not financial advice. Always do your own research.